Boston Scientific Files Proxy Materials
Ticker: BSX · Form: DEFA14A · Filed: Apr 29, 2024 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | DEFA14A |
| Filed Date | Apr 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, sec
TL;DR
BSC filed proxy docs, no fee. Standard procedure.
AI Summary
Boston Scientific Corporation filed a Definitive Additional Materials (DEFA14A) on April 29, 2024. This filing is related to their proxy statement and indicates no fee was required for this submission. The company is headquartered in Marlborough, MA, and operates in the surgical and medical instruments sector.
Why It Matters
This filing is a routine regulatory submission for Boston Scientific, providing updated information to shareholders regarding proxy matters. It ensures transparency and compliance with SEC regulations.
Risk Assessment
Risk Level: low — This filing is a standard regulatory disclosure and does not contain information that would typically indicate increased financial or operational risk.
Key Players & Entities
- Boston Scientific Corporation (company) — Registrant
- 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA 01752-1234 (company) — Business Address
- 508-683-4000 (company) — Business Phone
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for a proxy statement.
Who is the filing company?
The filing company is Boston Scientific Corporation.
When was this filing submitted?
The filing was submitted on April 29, 2024.
Is there a filing fee associated with this document?
No, the filing indicates 'No fee required'.
What is Boston Scientific Corporation's primary business sector?
Boston Scientific Corporation is in the 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS' sector, with SIC code 3841.
Filing Stats: 137 words · 1 min read · ~1 pages · Grade level 14.3 · Accepted 2024-04-29 16:58:58
Filing Documents
- a2024defa14a-emlvoteblastb.htm (DEFA14A) — 9KB
- emlbscproxy001.jpg (GRAPHIC) — 101KB
- emlbscproxy002.jpg (GRAPHIC) — 92KB
- emlbscproxy003.jpg (GRAPHIC) — 44KB
- 0000885725-24-000043.txt ( ) — 337KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a12 Boston Scientific Corporation (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box) No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 011 .